Jazz will acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones, gaining ABS-1230 for KCNT1+ epilepsy. ABS-1230 shows early seizure reductions and holds FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, with KYRON as registrational-ready; RDEP program acceptance adds speed potential. The deal strengthens Jazz's rare epilepsy leadership and expands its pipeline, potentially boosting long-term growth if ABS-1230 advances.
Jazz Pharmaceuticals is acquiring Actio Biosciences for $820 million upfront plus up to $500 million in milestones to gain ABS-1230, a KCNT1 inhibitor for KCNT1+ epilepsy. ABS-1230 has early proof-of-concept data and favorable regulatory designations with KYRON planned as the registrational study. The deal includes a spin-out of a new private entity, potentially broadening Jazz's rare-disease portfolio beyond epilepsy.
Jazz Pharmaceuticals posted Q2 EPS of $5.71, missing consensus $6.18, while revenue reached $1.208B. The company raised FY2026 sales guidance to $4.60-4.75B, signaling stronger demand and potential margin improvement. Shares climbed 1.4% in pre-market trading to $255 as analysts increased price targets on the improved outlook.
Analyst Jason Gerberry reaffirmed a Buy and lifted Jazz’s price target to $307, citing faster-than-expected Ziihera adoption supported by Phase III data. Peak Ziihera GEA sales are forecast around $1.3B, about 30% above prior estimates, suggesting a stronger launch and longer-term growth that could drive high-single-digit revenue CAGR through 2032. If realized, the stock could re-rate as the market prices in the improved growth trajectory.
Jazz reports positive Phase 3 Ziihera results; improved progression-free survival in GEA. Jazz acquired Ziihera development and commercialization rights from Zymeworks in 2022. Jazz shares jumped ~18%, Zymeworks ~30%, and BeOne/ONC also rose after the news. Jazz will present data in Q1 2026 and pursue NCCN guideline adoption and publication.
